(“cabaletta” or the “company”) (nasdaq: 08, 2022 (globe newswire) — cabaletta bio, inc. About cabaletta bio cabaletta bio (nasdaq:
Cabaletta intends to use the net proceeds from the offering, together with existing cash and cash equivalents, to fund the completion of preclinical development and the.